Resolution No. 177: The Two Post-Market Regulations Governing Medical Devices in Belarus

1. Key takeaways

The two core post-market procedures for medical devices in Belarus are established by two regulations approved by Council of Ministers Resolution No. 177 of 14 March 2024: the procedure for the collection, registration and analysis of adverse event (incident) information, and the procedures and conditions for withdrawal from circulation, return to the producer, or destruction. The Resolution was adopted under Article 39-1, paragraphs 9 and 13, of the Healthcare Law. Together, these two regulations form the backbone of everything a manufacturer must do after a device is placed on the Belarusian market: one regulation governs how safety information is gathered, registered and analyzed, and the other governs how a product is removed from circulation, returned to its producer, or destroyed. Understanding their structure, their legal basis and their current amendment status is a precondition for citing the post-market rules correctly in dossiers, procedures and correspondence with the authorities, and for avoiding the common mistake of treating information handling and physical disposal as a single undifferentiated obligation.

2. Legal basis

3. Expert insights

Insight 1: Resolution No. 177 addresses the entire post-market process of what to do after market entry. One regulation governs information — how adverse events are collected, registered and analyzed — and the other governs disposal — how products are withdrawn from circulation, returned to the producer or destroyed. Taken together, the two regulations constitute a closed loop that runs from the moment a problem is detected to the moment the disposal is completed and documented. Manufacturers who map their internal procedures onto this two-line structure find it easier to assign owners, deadlines and evidence requirements, because each line has its own logic: the information line is driven by timelines and analysis quality, while the disposal line is driven by procedural completeness and traceability.

Insight 2: the legal basis is Article 39-1, paragraphs 9 and 13, of the Healthcare Law. This matters because it shows that the Belarusian post-market rules follow the same structure as the registration rules — statutory authorization plus a government resolution. When manufacturers cite the post-market framework, they should follow a three-layer format: the statutory provision first, then Resolution No. 177, then the specific provision of the regulation. A citation that skips the statutory layer or jumps directly to the regulation reads as incomplete in correspondence with the authorities, and a consistent three-layer format also makes internal procedure documents easier to maintain when one of the layers is amended.

Insight 3: Resolution No. 177 has already been amended by Resolution No. 378. Resolution No. 378, which entered into force on 2026-07-30, amended both No. 211 and No. 177. The currently applicable version of Resolution No. 177 is therefore the amended version, and manufacturers should cite it as amended by Resolution No. 378 of 27 July 2026. Citing the original text without the amendment note creates a mismatch with the official register and can invalidate a otherwise correct argument about which authority now performs a given function, because the amendment is precisely what moved the adverse event functions to the new supervisory institution.

Insight 4: Union-level monitoring rules exist in parallel, and the two frameworks coexist. Board Decision No. 174 of the Eurasian Economic Commission establishes the Union-level monitoring rules and the tiered reporting deadlines. Belarus is a member of the Union, so when handling events that span several member states, manufacturers must take both the national regulation and the Union rules into account. The two frameworks are complementary rather than substitutive: the national regulation defines the domestic procedure and the domestic recipients, while the Union rules define the regional coordination logic. Union deadline figures must not be treated directly as national statutory deadlines, and national figures must not be assumed to satisfy Union obligations for events with cross-border reach.

4. Practical recommendations

1. Cite the post-market rules in the three-layer format. Article 39-1 of the Healthcare Law, then Resolution No. 177, then the specific provision of the regulation, in that order, in every dossier, procedure and official letter.
2. Note the amendment status when citing Resolution No. 177. Write that it is amended by Resolution No. 378, so that the citation matches the current official register and the transferred-function reality.
3. Manage the information line and the disposal line separately. Assign adverse event information to the information line and recalls and destruction to the disposal line, each with its own responsible person and its own deadlines, and reconcile the two lines at defined checkpoints.
4. Assess both rule sets for cross-member-state events. Check the national regulation and Union Decision No. 174 against each other for every event that touches more than one member state; neither replaces the other.

5. Verification checklist

• □ Confirmed that No. 177 (5/52905) entered into force on 2024-03-17 and that its Article 1 approves the two regulations
• □ Citations follow the three-layer format of law, resolution and regulation
• □ Citations of No. 177 note the amendment by No. 378 (in force 2026-07-30)
• □ The information line and the disposal line each have a responsible person and deadlines
• □ Cross-member-state events are assessed against both the national regulation and the Union rules

Regulatory information verified as of 30 October 2026.

In the Eurasian Economic Union market, GRZAN concentrates its core capabilities on three fronts. First, distinguishing the applicable conditions and the remaining time windows of the two channels — Union-level unified registration and national registration in each member state. The national registration procedure of Belarus has been fully restructured by Council of Ministers Resolution No. 211 of 28 April 2026 (state registration number 6-1/55925, in force 1 May 2026): the total time limit for preliminary technical work is compressed to 90 calendar days, the scope list is closed and implementing organizations are prohibited from expanding it, while the window for filing applications under the national procedure takes 31 December 2027 as the key milestone, so path selection must be decided in step with the time window. Second, local authorized representative services: GRZAN acts as the statutory representative of the manufacturer in Belarus, handling registration filings, responses to technical queries, changes to the registration dossier and post-market reporting obligations, and it has already synchronized its liaison mechanisms after Council of Ministers Resolution No. 378 of 27 July 2026 (in force 30 July 2026) transferred adverse event functions to the State Institution for State Pharmaceutical Supervision (Gosfarmnadzor). Third, quality system and testing support: GRZAN helps establish a quality management system conforming to ISO 13485 and organizes technical documentation according to the target path — the national path follows the annex to Ministry of Health Resolution No. 55, while the Union path follows Eurasian Economic Commission Council Decision No. 46. For post-market compliance in the Belarusian market — vigilance, recalls and responses to supervisory inspections — GRZAN provides end-to-end support built on the same framework.

Business enquiries: info@grzanglobal.com